Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT06124144
Other study ID # TT4CL_EKUT
Secondary ID 2021-004936-27
Status Terminated
Phase Phase 1
First received
Last updated
Start date June 21, 2023
Est. completion date February 27, 2024

Study information

Verified date June 2023
Source University Hospital Tuebingen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this interventional study is to assess the safety and tolerability of OlPC and to characterize the pharmacokinetics (PK) of OlPC following single, ascending doses administered orally in healthy-fed subjects.


Recruitment information / eligibility

Status Terminated
Enrollment 13
Est. completion date February 27, 2024
Est. primary completion date February 27, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: 1. Healthy males and females of non-childbearing (see below) potential. 1. 18 - 60 years of age. 2. BMI between 20-30 and body weight from 55-100 kg. 2. Females of non-childbearing potential defined as follows: 1. Surgically sterile (history of bilateral tubal ligation/occlusion, bilateral oophorectomy or hysterectomy) or 2. Postmenopausal, defined as amenorrhea for = 12 consecutive months prior to screening without an alternative medical cause. A follicle-stimulating hormone (FSH) level will be measured to confirm postmenopausal status. 3. Males must agree: 1. to use a latex condom during any sexual contact with while participating in the study and for 3 months following discontinuation from this study, even if he has undergone a successful vasectomy. 2. to refrain from donating semen or sperm during study participation and for 3 months after discontinuation from this study. 4. Able and willing (in the investigator's opinion) to comply with all trial requirements. 5. Available to participate in follow-up for the duration of trial. 6. Living in the area close enough to be able to attend all follow-up visits. 7. General good health based on the definition in BreithauptGrögler et al. 2017 and based on history, clinical examination and laboratory results. 8. Signed informed consent. 9. Consent to provide clinical history and if necessary consent that the study team is allowed to contact the family doctor of the participant. 10. All subjects are forbidden from donating blood while on study drug and for 3 months after discontinuation from this study Exclusion Criteria: 1. Any confirmed or suspected immunosuppressive or immunodeficient state, asplenia, recurrent, severe infections and chronic immunosuppressant medication (more than 14 days) within the past 6 months. 2. Any history of or signs of hepatic, renal, gastrointestinal, cardiovascular, endocrine, respiratory, immunologic, hematologic, dermatologic, or neurologic clinical significant abnormalities. 3. History of chronic infections (e.g., hepatitis ? or ?) and chronic inflammation. 4. History of significant, acute or chronic gastrointestinal, hepatic, cardiac or renal disorders. 5. History of leishmaniasis. 6. History of hypersensitivity to the excipients present in the investigational medicinal product or to any drug with similar chemical structure (Miltefosine). 7. Use of immunoglobulins or blood products within 3 months prior to enrolment. 8. Receipt of any investigational medicinal product in the 30 days preceding enrolment, or planned receipt during the trial period. 9. Participation in other clinical trials or observation period of competing trials. 10. History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ in the last five years). 11. Mental disorders or other psychiatric conditions (including depression). 12. The average alcohol intake greater than 24 g pure alcohol per day for men or greater than 12 g pure alcohol per day for women (including history of possible addiction) and alcohol consumption on more than five days a week. 13. Suspected or known injecting drug abuse in the 5 years preceding enrolment. 14. Participants unable to be closely followed for social, geographic or psychological reasons. 15. Any clinically significant abnormal finding on biochemistry or hematology blood tests, urine analysis or clinical examination. 16. History of seizure, except for sporadic childhood febrile convulsions. 17. Sjoegren-Larsson-Syndrome (SLS). 18. Participants who are unwilling to ingest the food provided. 19. Any other significant disease, disorder or finding which, in the opinion of the investigator, may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Oleylphosphocholine
The trial is a dose escalation trial that follows a 3+3 approach. The sample size is determined by a decision-making algorithm and by the tolerability of the study drug in the study participants. This design follows predetermined rules that help identify notable toxicities in time with a reasonable degree of accuracy. The initial dose will be 50mg OlPC (1 capsule) and participants in subsequent cohorts will receive 100mg (2 capsules), 150mg (3 capsules), 200mg (4 capsules), 250mg (5 capsules), or 300mg (6 capsules) if the previous doses are tolerated. The study ends when the last cohort is completed or when it is determined that a dose (within a cohort) is not tolerable.

Locations

Country Name City State
Germany Institute for Tropical Medicine Tübingen

Sponsors (1)

Lead Sponsor Collaborator
University Hospital Tuebingen

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Subject incidence of treatment-emergent adverse events at administration and follow-up visits Participants are followed up for 21 days and an additional telephone visit 35 days after drug administration will be conducted before dismissing the participant.
Secondary Cmax Maximum observed concentration in plasma after single dose (µg/mL) 21 days
Secondary Tmax Time of maximum observed concentration (h) 21 days
Secondary AUC0-t Area under the curve (AUC) from time 0 to the time of the last measurable concentration, calculated using the Linear Up / Log Down trapezoidal rule (h*µg/mL) 21 days
Secondary AUC0-24 Area under the curve from time 0 to hour 24 (single-dose only), calculated using the Linear Up / Log Down trapezoidal rule (h*µg/mL) 21 days
Secondary AUC0-inf Area under the curve from time 0 to infinity (single-dose only), calculated as AUC0-inf = AUC0-t + Ct / ?z, where Ct is the last observed quantifiable concentration and ?z is the elimination rate constant (h*µg/mL) 21 days
Secondary t1/2 Elimination half-life, calculated as ln(2) / ?z (h) 21 days
Secondary AUCres Residual Area: extrapolated area (single-dose) calculated as AUCres = 100 (AUC(0-inf) - AUC(0-t)) / AUC(0-inf) 21 days
See also
  Status Clinical Trial Phase
Completed NCT03641339 - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans N/A
Completed NCT04504435 - Safety, Tolerability and Pharmacokinetics (PK) Investigation of GSK3494245 in Healthy Participants Phase 1
Completed NCT00004755 - Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil Phase 2
Completed NCT00657618 - Use of Sodium Stibogluconate as a Treatment for Leishmaniasis Phase 1/Phase 2
Completed NCT04512742 - A Clinical Study to Develop a Controlled Human Infection Model Using Leishmania Major-infected Sand Flies N/A
Recruiting NCT00344188 - Diagnosis and Treatment of Leishmania Infections
Active, not recruiting NCT03009422 - Fractional CO2 Laser With Topical Pentostam Treatment for Cutaneous Leishmaniasis. N/A
Recruiting NCT05449717 - Incidence of Relapse and Post-Kala-Azar Dermal Leishmaniasis in South Sudan
Recruiting NCT06307171 - Human Leishmaniasis: Antigen Recognition Pattern and Study of New Potential Biomarkers N/A
Completed NCT01751048 - LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine Phase 1
Completed NCT00662012 - Sodium Stibogluconate Treatment of Leishmaniasis Phase 2
Completed NCT03993093 - Prevalence of HIV +ve Cases With AIDS Defining Opportunistic Infections Among ART Naive Patients Attending ART Centre
Recruiting NCT03784248 - Mediterranean Visceral Leishmaniasis With Leishmania Infantum
Withdrawn NCT02429505 - Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry
Completed NCT01377974 - Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis Phase 2
Completed NCT02656797 - Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis Phase 2
Completed NCT01484548 - Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers Phase 1
Completed NCT01300975 - Intralesional Antimony for Bolivian Cutaneous Leishmaniasis Phase 2
Completed NCT03294161 - Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis Phase 2
Completed NCT00401557 - Mechanisms Relating to the Distinct in Vitro Susceptibility of Human Macrophages to L. Viannia Infection

External Links